GENE ONLINE|News &
Ushering In A New Generation Of AI-Focused Investments Opportunities
Artificial intelligence (AI) has officially enamored the world with its plethora of potential applications. Optimistic folks see AI as a tool with the power to aid humanity and the technological revolution we live in. AI in the biotech sphere centers around drug discovery and drug repurposing. With a record number of AI-focused biotech companies forming, it is time to consider the applications, limitations, and the prospective future that investors face when confronted with AI startups looking for funding.
At the Digital Redefining Early Stage Investments (RESI) 2022 conference, Bill Kuziel, Ph.D. of MedPro Investors, sits down with three venture capital professionals to discuss the use of AI in biotechnology and its future during uncertain economic times.